RxDoctor Payments Data

Ashutosh Singh, MD

Nephrology · Oak Ridge, TNNPI 1538166376

Payments from drug & device makers

$1,312in general payments, 2019–2025

Across 45 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$161
  • Nxstage Medical, Inc.$129
  • Otsuka America Pharmaceutical, Inc.$123
  • Travere Therapeutics, Inc.$122
  • Amgen$112
  • Novo Nordisk$112
  • plus $552 from 11 others

What the payments were for

  • Food & beverage$1,03779%
  • Education$27521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,312 in reported general payments places this provider in the 45th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$259,894
Medicare patients
440
Services billed
1,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase18$492,198
VelphoroSucroferric Oxyhydroxide38$95,691
AuryxiaFerric Citrate17$31,686
LokelmaSodium Zirconium Cyclosilicate37$18,551
Sevelamer Carbonate104$11,553
Calcium Acetate47$3,685
Metolazone46$2,144
Calcitriol161$2,120
Bumetanide56$1,997
Chlorthalidone98$1,853
Hydralazine Hcl107$1,550
Midodrine Hcl39$1,467
Nifedipine ErNifedipine35$1,293
Torsemide81$1,186
Ondansetron Hcl34$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$112$492,19818 claims
Akebia Therapeutics IncAuryxia$25$31,68617 claims
AstraZenecaLokelma$161$18,55137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →